Related Experiment Video

Updated: Feb 16, 2026

miRNA Expression Analyses in Prostate Cancer Clinical Tissues
11:29

miRNA Expression Analyses in Prostate Cancer Clinical Tissues

Published on: September 8, 2015

11.3K

Genetic Association between Matrix Metalloproteinases Gene Polymorphisms and Risk of Prostate Cancer: A Meta-Analysis

Hong Weng1,2, Xian-Tao Zeng1,2, Xing-Huan Wang1,2

  • 1Department of Urology, Zhongnan Hospital of Wuhan University, Wuhan, China.

Frontiers in Physiology
|December 19, 2017
PubMed

Insights

This meta-analysis found that the matrix metalloproteinase (MMP)-2-1306 C/T polymorphism increases prostate cancer risk. The MMP-1-1607 1G/2G polymorphism may decrease risk in Caucasians.

Area of Science:

  • Genetics
  • Oncology
  • Molecular Biology

Background:

  • Prostate cancer risk may be influenced by matrix metalloproteinase (MMP)-2-1306 C/T and MMP-1-1607 1G/2G gene polymorphisms.
  • Previous studies have yielded controversial results, lacking pooled evidence on these associations.

Purpose of the Study:

  • To conduct a meta-analysis investigating the association between MMP-2-1306 C/T and MMP-1-1607 1G/2G polymorphisms and prostate cancer susceptibility.
  • To provide pooled evidence to clarify controversial findings in the existing literature.

Main Methods:

  • A comprehensive literature search was conducted across multiple databases (PubMed, EMBASE, CBM, CNKI, Wanfang) up to August 2016.
  • Odds ratios (ORs) and 95% confidence intervals (95% CIs) were calculated to assess the correlation between polymorphisms and prostate cancer risk.

Main Results:

  • The meta-analysis included six studies for MMP-2-1306 C/T (1,921 cases, 1,988 controls) and three studies for MMP-1-1607 1G/2G (438 cases, 394 controls).
  • MMP-2-1306 C/T polymorphism was associated with an elevated risk of prostate cancer (CT vs. CC: OR=1.78; TT+CT vs. CC: OR=1.62).
  • No significant association was found for MMP-1-1607 1G/2G, although a decreased risk was observed in Caucasians.

Conclusions:

  • The MMP-2-1306 C/T polymorphism is linked to an increased risk of developing prostate cancer.
  • The MMP-1-1607 1G/2G polymorphism might play an inhibitory role in prostate cancer occurrence among Caucasians.
  • Further research is recommended to validate these findings.
Keywords:
genetic variationmatrix metalloproteinasesmeta-analysispolymorphismprostate cancer

More Related Videos

CRISPR Gene Editing Tool for MicroRNA Cluster Network Analysis10:40

CRISPR Gene Editing Tool for MicroRNA Cluster Network Analysis

Published on: April 25, 2022

2.9K
An Orthotopic Murine Model of Human Prostate Cancer Metastasis06:48

An Orthotopic Murine Model of Human Prostate Cancer Metastasis

Published on: September 18, 2013

35.9K

Related Concept Videos

Genome-wide Association Studies-GWAS01:11

Genome-wide Association Studies-GWAS

Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
15.8K
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
10
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
15
Role of Matrix Metalloproteases in Degradation of ECM01:23

Role of Matrix Metalloproteases in Degradation of ECM

Matrix metalloproteases (MMPs) are enzymes involved in the hydrolysis of proteins and glycoproteins of the extracellular matrix. MMPs are essential for the migration and proliferation of cells through the dense matrix network, throughout embryonic development, and throughout morphogenesis. The first MMP activity discovered was a collagenase in a tadpole's tail undergoing metamorphosis. The active collagen deposition and modifications lead to the morphogenesis of tadpoles into the adult...
3.5K
Single Nucleotide Polymorphisms-SNPs01:05

Single Nucleotide Polymorphisms-SNPs

A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...
18.6K
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
9